Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;68(6):2062-2065.
doi: 10.1002/hep.30206. Epub 2018 Nov 12.

Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

Norihiro Imai  1 , David E Cohen  1
Affiliations
Editorial

Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

Norihiro Imai et al. Hepatology. 2018 Dec.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. Liver-directed inhibition of ACC enhances fatty acid β-oxidation and reduces de novo lipogenesis but increases VLDL secretion.
Liver directed inhibition of ACC1 and ACC2 reduces de novo lipogenesis and increases fatty acid β-oxidation (4,6). Despite reductions in triglycerides content in the liver and improvements in insulin sensitivity, liver-directed inhibition of ACC1 and ACC2 leads to a decrease in polyunsaturated fatty acids, increase in SREBP1c, GPAT1 expression and VLDL secretion, eventually leading to hypertriglyceridemia. Fibrate drugs decrease plasma triglycerides by enhancing fatty acid oxidation in the liver and by promoting lipoprotein lipase-mediated triglyceride clearance from the plasma.
See this image and copyright information in PMC

Comment on

References

    1. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest 2005;115:1343–51. - PMC - PubMed
    1. Harada N, Oda Z, Hara Y, Fujinami K, Okawa M, Ohbuchi K, et al. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol. Cell. Biol 2007;27:1881–8. - PMC - PubMed
    1. Abu-Elheiga L, Wu H, Gu Z, Bressler R, Wakil SJ. Acetyl-CoA carboxylase 2 −/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J. Biol. Chem 2012;287:12578–12588. - PMC - PubMed
    1. Goedeke L, Bates J, Vatner DF, Perry RJ, Wang T, Ramirez R, et al. Acetyl-CoA Carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia. Hepatology. 2018; - PMC - PubMed
    1. Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz E, Gitlin N, et al. Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to significant improvements in MRI-PDFF in a phase 2, randomized, placebo controlled trial of patients with NASH. Hepatology. 2017;66:1260A–1261A.

Substances